Delivra Health Brands Inc(DHB)
(DHB)
Q3-rapport
Endast PDF
68 dagar sedan
Orderdjup
Stängd
Antal
Köp
417 000
Sälj
Antal
3 000
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Volymvägt snittpris (VWAP)
-VWAP
-Omsättning (CAD)
-Mäklarstatistik
Ingen data hittades
Företagshändelser
| Nästa händelse | |
|---|---|
Kalender är inte tillgänglig | |
| Tidigare händelser | ||
|---|---|---|
| 2024 Q3-rapport | 15 maj | |
| 2024 Q2-rapport | 27 feb. | |
| 2024 Q1-rapport | 28 nov. 2023 | |
| 2023 Q4-rapport | 18 okt. 2023 | |
| 2023 Q3-rapport | 23 maj 2023 |
Data hämtas från Quartr
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Q3-rapport
Endast PDF
68 dagar sedan
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Företagshändelser
| Nästa händelse | |
|---|---|
Kalender är inte tillgänglig | |
| Tidigare händelser | ||
|---|---|---|
| 2024 Q3-rapport | 15 maj | |
| 2024 Q2-rapport | 27 feb. | |
| 2024 Q1-rapport | 28 nov. 2023 | |
| 2023 Q4-rapport | 18 okt. 2023 | |
| 2023 Q3-rapport | 23 maj 2023 |
Data hämtas från Quartr
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
8 juli8 juliDelivra Health Brands Inc. (TSX-V:DHB) is expanding its reach in the Middle East, working with its partner in the region to bring its Dream Water product to pharmacies across the United Arab Emirates. In a recent interview with Proactive, CEO Gord Davey shared insights into the company’s strategic move to enter the country amid rising demand for sleep aids. Proactive: You're just back from Dubai, where you have opened a new sales territory targeting the United Arab Emirates with your partner and distributor in the region. Tell us more about that. Gord Davey: It was a wonderful trip over to the UAE, where we are working with one of our current partners, that we are expanding our territories throughout the Middle East. And it's one of the things that we told our shareholders that we would do is to continue our expansion of our brands. We were fortunate to work with our partners out of Saudi Arabia and now we have opened up the UAE region. I spent some time in Dubai last week, with our first order and, watching the first truckload come in and, get delivered to the first customer. So, it was a very, very good trip. Why Dubai and the UAE? That's a great question. It’s an expansion with our partners out of our Middle East-Saudi Arabia area. We have a tremendous partner over there and the expansion of Dream Water continues to grow exponentially in the Middle East. We have it registered as a drug product and we are in all of the pharmacies throughout Saudi Arabia. Now it will be in the pharmacies throughout the UAE as well. So it's a growing product, our Dream Water brand, in the Middle East and we continue to grow in territories over there. Did you face any challenges moving into that market due to regulations in the Middle East, or has it been seamless? No, that's again something that we've really had to work on. This is a culmination of great efforts over the past nine months to get registered in this area. It does take a lot of time to get everything, approved and registered through the proper regulatory channels. The good thing about it is that we have a tremendous partner over there that knows how to work through these things. It's a combination of the last nine months and we're very fortunate to now be able to deliver in the UAE. Tell us about the potential you're seeing in that market and the size of the potential market. Again, it's an expansion of what we're currently doing. All over the world, there are issues with people having the ability to get a good night's sleep, and Dream Water has really caught on to the marketplace over there. The pharmacists inside the pharmacies, they recommend our Dream Water product to those who are having a hard time sleeping. In the UAE, the population is growing exponentially there as well. What a wonderful area to continue to grow our brand. As you go global, which other territories are you looking at? Are you able to tell us? We are working through regulatory pieces on that. What I can say is that there will be definite expansion in the Middle East as well. We'll continue to grow and add countries and territories in that region. I can't say anything until we have all the regulatory pieces done. But you can rest assured that we continue to grow globally.- 28 maj28 majDelivra Health Brands Inc. (CVE:DHB) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. The CA$13m market-cap company posted a loss in its most recent financial year of CA$184k and a latest trailing-twelve-month loss of CA$708k leading to an even wider gap between loss and breakeven. Many investors are wondering about the rate at which Delivra Health Brands will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company. Check out our latest analysis for Delivra Health Brands According to some industry analysts covering Delivra Health Brands, breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of CA$163k in 2025. So, the company is predicted to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 167% is expected, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. earnings-per-share-growth TSXV:DHB Earnings Per Share Growth May 23rd 2024 Given this is a high-level overview, we won’t go into details of Delivra Health Brands' upcoming projects, however, keep in mind that typically pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments. One thing we would like to bring into light with Delivra Health Brands is its relatively high level of debt. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in Delivra Health Brands' case is 57%. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.
- 8 maj8 majAutomatisk teknisk analyse. Middels lang sikt, 7. mai 2024 Delivra Health Brands Inc viser en sterk utvikling innenfor en stigende trendkanal på mellomlang sikt. Stigende trender indikerer at bedriften er inne i en positiv utvikling og at kjøpsinteressen blant investorene er økende. Aksjen ga kjøpssignal fra en rektangelformasjon ved bruddet opp gjennom motstanden ved 0.04 . Videre oppgang til 0.05 eller mer er signalisert. Det er ingen motstand i kursdiagrammet og en videre oppgang indikeres. Ved reaksjoner tilbake har aksjen støtte ved cirka 0.03 . Det er dårlig likviditet i aksjen (handlet 95% av dagene, middel 0.01 mill kr per dag), noe som svekker analysen.
7 maj7 majTo the moon friends! :)7 maj7 majDo you know why it's going up?8 maj8 majOnly the positive direction with profitability comes to mind. The new leadership has successfully turned the tide.- 26 mars26 marsDelivra Health Brands Announces Adoption of a New Fixed Share Option Plan March 20, 2024 – Vancouver, British Columbia – Delivra Health Brands Inc. ("Delivra Health" or the "Company") (TSX-V: DHB; OTCQB: DHBUF), a consumer packaged goods company uniquely positioned in the health and wellness sector, announced today that its Board of Directors has adopted a new 10% fixed stock option plan (the “Stock Option Plan”), which has been approved by the TSX Venture Exchange ("TSXV"). The Stock Option Plan replaces the Company’s previous 10% fixed stock option plan, announced on July 14, 2020 (the "Predecessor Plan"). Under the Stock Option Plan, the Company may grant options to acquire up to 31,261,785 common shares of the Company, representing 10% of the Company’s current issued and outstanding common shares, subject to the terms and conditions prescribed by the TSXV, and applicable securities laws. Any options outstanding under the previous stock option plan will be governed by the new Stock Option Plan
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Q3-rapport
Endast PDF
68 dagar sedan
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
- 8 juli8 juliDelivra Health Brands Inc. (TSX-V:DHB) is expanding its reach in the Middle East, working with its partner in the region to bring its Dream Water product to pharmacies across the United Arab Emirates. In a recent interview with Proactive, CEO Gord Davey shared insights into the company’s strategic move to enter the country amid rising demand for sleep aids. Proactive: You're just back from Dubai, where you have opened a new sales territory targeting the United Arab Emirates with your partner and distributor in the region. Tell us more about that. Gord Davey: It was a wonderful trip over to the UAE, where we are working with one of our current partners, that we are expanding our territories throughout the Middle East. And it's one of the things that we told our shareholders that we would do is to continue our expansion of our brands. We were fortunate to work with our partners out of Saudi Arabia and now we have opened up the UAE region. I spent some time in Dubai last week, with our first order and, watching the first truckload come in and, get delivered to the first customer. So, it was a very, very good trip. Why Dubai and the UAE? That's a great question. It’s an expansion with our partners out of our Middle East-Saudi Arabia area. We have a tremendous partner over there and the expansion of Dream Water continues to grow exponentially in the Middle East. We have it registered as a drug product and we are in all of the pharmacies throughout Saudi Arabia. Now it will be in the pharmacies throughout the UAE as well. So it's a growing product, our Dream Water brand, in the Middle East and we continue to grow in territories over there. Did you face any challenges moving into that market due to regulations in the Middle East, or has it been seamless? No, that's again something that we've really had to work on. This is a culmination of great efforts over the past nine months to get registered in this area. It does take a lot of time to get everything, approved and registered through the proper regulatory channels. The good thing about it is that we have a tremendous partner over there that knows how to work through these things. It's a combination of the last nine months and we're very fortunate to now be able to deliver in the UAE. Tell us about the potential you're seeing in that market and the size of the potential market. Again, it's an expansion of what we're currently doing. All over the world, there are issues with people having the ability to get a good night's sleep, and Dream Water has really caught on to the marketplace over there. The pharmacists inside the pharmacies, they recommend our Dream Water product to those who are having a hard time sleeping. In the UAE, the population is growing exponentially there as well. What a wonderful area to continue to grow our brand. As you go global, which other territories are you looking at? Are you able to tell us? We are working through regulatory pieces on that. What I can say is that there will be definite expansion in the Middle East as well. We'll continue to grow and add countries and territories in that region. I can't say anything until we have all the regulatory pieces done. But you can rest assured that we continue to grow globally.
- 28 maj28 majDelivra Health Brands Inc. (CVE:DHB) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. The CA$13m market-cap company posted a loss in its most recent financial year of CA$184k and a latest trailing-twelve-month loss of CA$708k leading to an even wider gap between loss and breakeven. Many investors are wondering about the rate at which Delivra Health Brands will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company. Check out our latest analysis for Delivra Health Brands According to some industry analysts covering Delivra Health Brands, breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of CA$163k in 2025. So, the company is predicted to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 167% is expected, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. earnings-per-share-growth TSXV:DHB Earnings Per Share Growth May 23rd 2024 Given this is a high-level overview, we won’t go into details of Delivra Health Brands' upcoming projects, however, keep in mind that typically pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments. One thing we would like to bring into light with Delivra Health Brands is its relatively high level of debt. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in Delivra Health Brands' case is 57%. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.
- 8 maj8 majAutomatisk teknisk analyse. Middels lang sikt, 7. mai 2024 Delivra Health Brands Inc viser en sterk utvikling innenfor en stigende trendkanal på mellomlang sikt. Stigende trender indikerer at bedriften er inne i en positiv utvikling og at kjøpsinteressen blant investorene er økende. Aksjen ga kjøpssignal fra en rektangelformasjon ved bruddet opp gjennom motstanden ved 0.04 . Videre oppgang til 0.05 eller mer er signalisert. Det er ingen motstand i kursdiagrammet og en videre oppgang indikeres. Ved reaksjoner tilbake har aksjen støtte ved cirka 0.03 . Det er dårlig likviditet i aksjen (handlet 95% av dagene, middel 0.01 mill kr per dag), noe som svekker analysen.
- 7 maj7 majTo the moon friends! :)7 maj7 majDo you know why it's going up?8 maj8 majOnly the positive direction with profitability comes to mind. The new leadership has successfully turned the tide.
- 26 mars26 marsDelivra Health Brands Announces Adoption of a New Fixed Share Option Plan March 20, 2024 – Vancouver, British Columbia – Delivra Health Brands Inc. ("Delivra Health" or the "Company") (TSX-V: DHB; OTCQB: DHBUF), a consumer packaged goods company uniquely positioned in the health and wellness sector, announced today that its Board of Directors has adopted a new 10% fixed stock option plan (the “Stock Option Plan”), which has been approved by the TSX Venture Exchange ("TSXV"). The Stock Option Plan replaces the Company’s previous 10% fixed stock option plan, announced on July 14, 2020 (the "Predecessor Plan"). Under the Stock Option Plan, the Company may grant options to acquire up to 31,261,785 common shares of the Company, representing 10% of the Company’s current issued and outstanding common shares, subject to the terms and conditions prescribed by the TSXV, and applicable securities laws. Any options outstanding under the previous stock option plan will be governed by the new Stock Option Plan
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Orderdjup
Stängd
Antal
Köp
417 000
Sälj
Antal
3 000
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Volymvägt snittpris (VWAP)
-VWAP
-Omsättning (CAD)
-Mäklarstatistik
Ingen data hittades
Företagshändelser
| Nästa händelse | |
|---|---|
Kalender är inte tillgänglig | |
| Tidigare händelser | ||
|---|---|---|
| 2024 Q3-rapport | 15 maj | |
| 2024 Q2-rapport | 27 feb. | |
| 2024 Q1-rapport | 28 nov. 2023 | |
| 2023 Q4-rapport | 18 okt. 2023 | |
| 2023 Q3-rapport | 23 maj 2023 |
Data hämtas från Quartr